 Seagen Inc NASDAQ: SGEN announced data from a Phase 1 trial combining SEA-CD40 with chemotherapy and an anti-PD-1 in patients with metastatic pancreatic ductal adenocarcinoma PDAC. The data were shared at the ASCO GI annual meeting. 